Abstract
Purpose: The present study was designed to examine the pharmacokinetics of a fluocinolone acetonide (FA) intravitreal implant in pigmented rabbits. Methods: Pigmented rabbits were randomly assigned to receive either a 0.5 mg or 2.0 mg FA intravitreal implant (Retisert™). Four animals were sacrificed per time point (2 hours; 2 weeks; and 3, 6, 9, and 12 months after implantation) for FA intraocular levels determination. Results: In the vitreous, concentration of FA was relatively constant from the first time point, 2 hours, through 1 year, and dose-related, approximately seven- to eight-fold greater in the 2-mg implant. Concentrations of FA were generally higher in the vitreous (11–18 and 75–146 ng/g) and retina (42–87 and 224–489 ng/g) than in the aqueous humor (0.21–1.1 and 2.6–13.0 ng/g) for the 0.5- and 2-mg implants, respectively. Urine and plasma values were below the lower limit of quantitation (200 pg/mL) for all observations, indicating no evidence of systemic absorption. Conclusions: In this rabbit study, the Retisert™ provides relatively constant levels of FA in the posterior pole, which is consistent with previous reports of its clinical utility.
Get full access to this article
View all access options for this article.